CSIMarket Company Name, Ticker, Industry, else..
 
Ibio inc   (NASDAQ: IBIO)
 
Price: $1.3050 $0.13 10.593%
Day's High: $1.3099000453948975 Week Perf: 7.85 %
Day's Low: $ 1.21 30 Day Perf: -10 %
Volume (M): 1,557,046 52 Wk High: $ 3.82
Volume (M$): $ 0 52 Wk Avg: $1.70
Open: $1.25 52 Wk Low: $0.77



 Market Capitalization (Millions $) 136
 Shares Outstanding (Millions) 104
 Employees 23
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -33
 Cash Flow (TTM) (Millions $) 39
 Capital Exp. (TTM) (Millions $) 1

Business Description


Ibio Inc. is a biotechnology company based in the United States. It primarily focuses on the development and commercialization of plant-based therapies and vaccines. Ibio utilizes a proprietary technology platform called FastPharming, which enables the rapid production of biologics using plants. The company collaborates with various partners to develop and manufacture therapeutic candidates for diseases such as cancer, fibrosis, and infectious diseases. Ibio also offers contract development and manufacturing services to other pharmaceutical and biotechnology companies.


   Company Address: 11750 Sorrento Valley Road San Diego 92121 CA
   Company Phone Number: 446-0027   Stock Exchange / Ticker: NASDAQ IBIO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ACAD   -0.94%    
BMY   -0.6%    
PFE        0.34% 
REGN   -1.32%    
UTHR   -1.79%    
VRTX   -0.28%    
• View Complete Report
   



Clinical Study

The biotechnology landscape is on the cusp of a significant evolution, heralded by promising advancements f...

Published Mon, Apr 7 2025 11:44 AM UTC

Revolutionizing Muscle Regeneration: iBio s Groundbreaking Advances in Anti-Myostatin Antibody Therapy The biotechnology landscape is on the cusp of a significant evolution, heralded by promising advancements from iBio, Inc. a pioneering bio-pharmaceutical company. iBio has released compelling new data on IBIO-600, its potentially best-in-class long-acting anti-myostatin ant...
Product Service News

iBio Expands Cardiometabolic and Obesity Research with Innovative Bispecific Antibody Program

Published Thu, Jan 2 2025 12:32 PM UTC

: iBio Inc. has announced an expansion of its cardiometabolic and obesity program through the development of a novel bispecific antibody targeting Myostatin and Activin A, building upon the success of its existing anti-Myostatin program. This new therapy aims to promote weight loss, prevent muscle loss, and mitigate weight regain while potentially offering less frequent do...
Contract

iBio Successfully Closes Sale of Texas Manufacturing Facility, Alleviating $13.2M of Secured Debt

Published Mon, Jun 3 2024 11:00 AM UTC

In recent developments, prominent biopharmaceutical company iBio Inc. has closed the sale of its manufacturing facility located in Texas. This transaction has successfully eliminated approximately $13.2 million of secured debt, signaling significant progress towards the company s financial restructuring. This article aims to provide an overview of this important development...
Partnership

Augmenting Obesity and Cardiometabolic Disease Treatment: iBio and AstralBio's Transformative AI Collaboration

Published Wed, Mar 27 2024 11:00 AM UTC

The fight against obesity and cardiometabolic diseases continues to present significant challenges for the healthcare industry. However, a beacon of hope arises as two leading innovators, iBio and AstralBio, join forces in a transformative collaboration. Harnessing the power of Artificial Intelligence (AI) and precision biologics, this groundbreaking partnership aims to rapi...
Financing Agreement

iBio Secures $15 Million Private Placement with Significant Premium, Bolstering Growth Prospects

Published Tue, Mar 26 2024 11:35 PM UTC

iBio Announces Successful $15.0 Million Private Placement with Significant Premium to Last Close
iBio, a leading biologics contract manufacturing organization, has recently announced a successful private placement offering that raised $15.0 million. The purchase price of $2.85 per share represents a premium of over 148% to the last closing price, indicating strong invest...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 1,357.98
Price to Sales (Expected) -
Price to Book 1.58
PEG (TTM) -

Financial Strength Current
Quick Ratio 7.5
Working Capital Ratio 7.85
Leverage Ratio (MRQ) 0.16
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.36 $
Revenues (TTM) 0 $
Cash Flow (TTM) 0.38 $
Cash 0.85 $
Book Value 0.82 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,436,696
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.